Literature DB >> 6825030

Perinatal transmission of hepatitis B virus.

R K Chaudhary.   

Abstract

Transmission of hepatitis B virus from carrier mothers to their infants seems most likely to occur during birth. Both cord blood and breast milk have been found to be positive (in 35% and 72% of cases respectively) for hepatitis B surface antigen (HBsAg), but they do not appear to play an important role in transmission. To control this problem high-risk women should be tested during pregnancy for HBsAg. The infants of infected women should be given several doses of hepatitis B immunoglobulin starting at birth. In less developed regions, where hepatitis B is endemic, administration of the immunoglobulin in combination with vaccine, or even the vaccine alone, may be preferable in order to provide infants with lasting protection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6825030      PMCID: PMC1875192     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  27 in total

1.  Vertical transmission of hepatitis B antigen in Taiwan.

Authors:  C E Stevens; R P Beasley; J Tsui; W C Lee
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

2.  Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients.

Authors:  J Crosnier; P Jungers; A M Couroucé; A Laplanche; E Benhamou; F Degos; B Lacour; P Prunet; Y Cerisier; P Guesry
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

3.  Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial.

Authors:  R P Beasley; L Y Hwang; C C Lin; C E Stevens; K Y Wang; T S Sun; F J Hsieh; W Szmuness
Journal:  Lancet       Date:  1981-08-22       Impact factor: 79.321

4.  Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).

Authors:  P Maupas; J P Chiron; F Barin; P Coursaget; A Goudeau; J Perrin; F Denis; I D Mar
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

5.  Distribution of hepatitis B e antigen (HBeAg) and anti-HBe in carriers with different levels of HBsAg.

Authors:  N Nath; C T Fang; H A Fields; I L Doto; J E Maynard
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

6.  Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen.

Authors:  K Shiraki; N Yoshihara; M Sakurai; T Eto; T Kawana
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

7.  High titer multiple dose therapy with HBIG in newborn infants of HBsAg positive mothers.

Authors:  R Jhaveri; W Rosenfeld; J D Salazar; H Dosik; C C Cheng; H E Evans
Journal:  J Pediatr       Date:  1980-08       Impact factor: 4.406

8.  Vertical transmission of the hepatitis B surface antigen.

Authors:  I L Schweitzer
Journal:  Am J Med Sci       Date:  1975 Sep-Oct       Impact factor: 2.378

9.  The e antigen and vertical transmission of hepatitis B surface antigen.

Authors:  R P Beasley; C Trepo; C E Stevens; W Szmuness
Journal:  Am J Epidemiol       Date:  1977-02       Impact factor: 4.897

10.  Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant.

Authors:  V C Wong; A K Lee; H M Ip
Journal:  Br J Obstet Gynaecol       Date:  1980-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.